T3D Therapeutics, Inc. Receives FDA IND Approval to Begin Phase 2 Clinical Study of T3D-959 in Alzheimer’s Patients

Jun 22, 2015 | News | 0 comments

Phase 2a Clinical Trial of a Novel Nuclear Receptor Agonist in Alzheimer’s patients expected
to initiate in 3Q2015.